Therapeutic Angiogenesis Using HGF Plasmid

DOI Web Site 被引用文献2件 参考文献56件 オープンアクセス
  • Sanada Fumihiro
    Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine
  • Fujikawa Tatsuya
    Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine
  • Shibata Kana
    Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine
  • Taniyama Yoshiaki
    Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine
  • Rakugi Hiromi
    Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine
  • Morishita Ryuichi
    Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine

この論文をさがす

抄録

<p>Hepatocyte growth factor (HGF) is secreted from stromal and mesenchymal cells, and its receptor cMet is expressed on various types of cells such as smooth muscle cells, fibroblast, and endothelial cells. HGF stimulates epithelial and endothelial cell proliferation, motility, and morphogenesis in a paracrine and autocrine manner, organizing multistep of angiogenesis in many organs. In addition, HGF is recognized as a potent anti-inflammatory and anti-fibrotic growth factor, which has been proved in several animal studies, including neointimal hyperplasia and acute myocardial infarction model in rodent. Thus, as compared to other angiogenic growth factors, HGF exerts multiple effects on ischemic tissues, accompanied by the regression of tissue inflammation and fibrosis. These data suggest the therapeutic potential of the HGF for peripheral artery disease as it being accompanied with chronic tissue inflammation and fibrosis. In the present narrative review, the pleiotropic action of the HGF that differentiates it from other angiogenic growth factors is discussed first, and later, outcomes of the human clinical study with gene therapy are overviewed.</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (56)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ